Bristol Myers Squibb Announces Key Findings from Phase 2/3 ‘Relativity-047’ Study Evaluating Fixed-Dose Combination of Relatlimab, an Anti-LAG-3 Antibody, and Nivolumab versus Nivolumab Monotherapy in Patients with Metastatic Melanoma or unresectable not previously treated. The study met the primary endpoint of progression-free survival (PFS). Follow-up for overall survival, a secondary endpoint, is ongoing. The fixed dose combination was well tolerated and no new safety signals were reported in either the relatlimab and nivolumab combination arm or the nivolumab monotherapy arm. Relatlimab is the third distinct checkpoint inhibitor for Bristol Myers Squibb and, with nivolumab, the first fixed-dose combination to demonstrate a benefit for patients. BMS will present the results at an upcoming conference and will discuss these results with regulatory authorities.
“Immune checkpoint inhibitors alone or in combination have transformed treatment and improved survival rates for patients with metastatic or unresectable melanoma. However, there remains a considerable number of patients who could benefit from a new combination therapy that affects pathways. cell phones potentially complementary to enhance anti-tumor activity, “said Jonathan Cheng, senior vice president and head of oncology development, Bristol Myers Squibb.
“The results of this study suggest that targeting the LAG-3 pathway in combination with PD-1 inhibition may prove to be a key strategy to enhance immune responses and help improve outcomes in these patients,” concludes Cheng.
The gene 3 for the activation of lymphocytes (LAG-3) is a surface molecule expressed on effector and regulatory T cells (Treg). LAG-3 regulates the pathway of an inhibitory-type immune checkpoint that limits the activity of T cells, resulting in impaired ability to attack tumor cells. In situations of chronic persistence of diseases such as cancer, T cells manifest progressive functional exhaustion characterized by an upregulation of inhibitory immune checkpoints such as PD-1 and LAG-3. Although LAG-3 and PD-1 are distinct immune checkpoint pathways, they can potentially act synergistically on effector T cells leading to functional depletion of T cells.
Relatlimab is an inhibitory antibody that binds to LAG-3 on T cells, restoring the effector function of depleted T cells. Relatlimab, in combination with nivolumab, is the first anti-LAG-3 antibody to demonstrate a benefit for patients.